Eli Lilly and Company said that a Phase 2b study of baricitinib, a JAK inhibitor being developed for rheumatoid arthritis, reached its primary endpoint by showing a statistically significant response as measured by a scoring system. ---Subscribe to MedNous to access this article--- Clinical Research Company News
